Featured Bioprocessing Editorial

1. Sorriso's Path To Oral Biologics Dosing Is Through The Gut 6/30/2025

   Following positive results from a Phase 1b trial, company leaders describe scaling their yeast expression and spray-drying processes as they prepare for Phase 2.

2. Why 'Which Is Best?' Is The Wrong Question In CGT Development 6/27/2025

   In cell therapy development, the instinct to seek a single “best” option is natural — but in reality, there’s rarely a universal winner.

3. Understanding FDA's New National Priority Voucher Pilot Program 6/25/2025

   The FDA's vouchers will be issued to companies addressing health issues in the U.S. and increasing domestic manufacturing, among other criteria.

4. The Latest Techniques And Technology For Differentiating Capsids 6/24/2025

   Since AAV gene therapy’s origins, scientists and regulators have sought optimized ways to measure empty/full capsids. This expert reviews pros and cons of modern methods.

5. AI-Assisted QMS: Bridging ISO/IEC 42001:2023 And ICH Q10 For Pharmaceutical Excellence 6/23/2025

   Integrating AI into quality management systems (QMS) can be a transformative opportunity to enhance quality assurance, improve compliance, and enable proactive risk management. 

6. Navigating FDA Regulatory Changes: Policy Shifts, Deregulation, Restructuring, And Future Oversight 6/23/2025

   Recent shifts within the U.S. FDA reflect an increasingly complex tension between scientific rigor and accelerating political and economic pressures. Here are the newest developments and emerging focal points.

7. Ask The Pros — The Latest In Downstream HCP Mitigation 6/20/2025

   Two downstream biologics processing experts address some of the field's complex, nagging questions about mitigating host cell proteins.

8. How Is RIM Software Transforming Regulatory Compliance? 6/20/2025

   Regulatory information management (RIM) software tools streamline global regulatory processes on a single cloud-based platform throughout the entire product life cycle.

9. Draft EMA Doc Proposes More Flexibility On Biosimilar CES Requirements 6/19/2025

   Clinical efficacy studies may not be necessary under certain conditions, writes the European Medicines Agency in a new draft reflection paper.

10. Exploring The Market For Closed-Loop Cell Therapy Production 6/18/2025

    The second part of a discussion on closed-loop systems explores the CDMO and equipment landscape for scaling automated closed loop cell therapy manufacturing systems.